Results 61 to 70 of about 10,834 (260)
Molecular Oncology, EarlyView.EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain +10 more
wiley +1 more source
Carbon Footprint, Financial Structure, and Firm Valuation: An Empirical Investigation
RisksThis study aims to investigate the complex link between carbon emissions, firm value, and financial choice in regard to the GCC, a dynamic emerging economy.
István Hágen, Amanj Mohamed Ahmed
doaj +1 more source
Firm valuation and accounting numbers [PDF]
Estudos de Gestão - Portuguese Journal of Management Studies, 2000 Accounting information on earnings and book values is commonly used to help value a firm. The errors that arise from the use of these data stem from the fact that accounting depreciation is not generally equal to expected economic depreciation and that earnings are liable to random shocks.
openaire +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Investability and Firm Value [PDF]
We study how investability, or openness to foreign equity investors, affects firm value in a sample of over 1,400 firms from 26 emerging markets. We find that, on average, investability is associated with a 9% valuation premium (as measured by Tobin's q).
Thomas O'Connor, Todd Mitton
core
, 2020 The corporate cash holdings are important when deciding performance and profitability of firms, and also as an extension to shareholders’ wealth. The issue of the amount of cash holdings in firms does not solely impact the firms’ balance sheets and ...
Mohd Ashhari, Zariyawati +2 more
core +1 more source
To Investigate the Growth in Expected Earnings and Equity Valuation [PDF]
Faslnāmah-i Pizhūhish/Nāmah-i Iqtisādī, 2007 This paper develops an equity valuation model that relates growth in expected earnings to firm value. The modelling, in addition to growth, also incorporates nonrecurring items as an adjustment for earnings. The analysis shows that the valuation function
Hashem Nikoomaram, Roya Darabi
doaj
Pass-Through and C Corp Outputs under TCJA
International Journal of Financial Studies, 2020 Corporate finance research focuses on C corps (CCs) neglecting pass-throughs (PTs). We answer this neglect by examining PT outputs for the categories of debt choice, valuation, and leverage gain. In the process, we expand on the nongrowth PT research and
Robert Hull
doaj +1 more source
Molecular Oncology, EarlyView.We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
A valuation model for firms with stochastic earnings [PDF]
In this paper, a model is set up for valuing a firm with stochastic earnings. It is assumed that the earnings of the considered firm follow a time-varying mean reverting stochastic process.
Steven Li
core +1 more source